Role of DNA Repair-related Gene Polymorphisms in Susceptibility to Risk of Prostate Cancer

  • Yang, Bo (Department of Urology Surgery, Shanghai Pudong New Area Zhoupu Hospital) ;
  • Chen, Wei-Hua (Department of Urology Surgery, Shanghai East Hospital Affiliated to Tongji University) ;
  • Wen, Xiao-Fei (Department of Urology Surgery, Shanghai East Hospital Affiliated to Tongji University) ;
  • Liu, Hui (Department of Urology Surgery, Shanghai Pudong New Area Zhoupu Hospital) ;
  • Liu, Feng (Department of Urology Surgery, Shanghai Pudong New Area Zhoupu Hospital)
  • Published : 2013.10.30


Aim: We assessed the association between genetic variants of XPG, XPA, XPD, CSB, XPC and CCNH in the nucleotide excision repair (NER) pathway and risk of prostate cancer. Methods: We genotyped the XPG, XPA, XPD, CSB, XPC and CCNH polymorphisms by a 384-well plate format on the MassARRAY(R) platform. Multivariate logistical regression analysis was used to assess the associations between the six gene polymorphisms and risk of prostate cancer. Results: Individuals carrying the XPG rs229614 TT (OR=2.01, 95%CI=1.35-3.27) genotype and T allele (OR=1.73, 95%CI=1.37-2.57) were moderately significantly associated with a higher risk of prostate cancer. Subjects with XPD rs13181 G allele had a marginally increased risk of prostate cancer, with adjusted OR(95%CI) of 1.53 (1.04-2.37). Moreover, individuals carrying with CSB rs2228526 GG genotype (OR=2.05, 95% CI=1.23-3.52) and G allele (OR=1.56, 95%CI=1.17-2.05) were associated with a higher increased risk of prostate cancer. The combination genotype of XPG rs2296147 T and CSB rs2228526 G allele had accumulative effect on the risk of this cancer, with an OR (95% CI) of 2.23(1.37-3.59). Conclusions: Our study indicates that XPG rs2296147 and CSB rs2228526 polymorphisms are significantly associated with increased risk of prostate cancer, and that combination of XPG rs2296147 T allele and CSB rs2228526 G allele is strongly associated with an increased risk.


XPG;CSB;DNA repair;related genes;prostate cancer;polymorphism


  1. Sun XH, Hou WG, Zhao HX, et al (2013). Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors. Asian Pac J Cancer Prev, 14, 2049-52.
  2. Nock NL, Cicek MS, Li L, et al (2006). Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis, 27, 1842-8.
  3. Priyadarshini A, Chakraborti A, Mandal AK, Singh SK (2013). Asp299Gly and Thr399Ile polymorphism of TLR-4 gene in patients with prostate cancer from North India. Indian J Urol, 29, 37-41.
  4. Rybicki BA, Nock NL, Savera AT, Tang D, Rundle A (2006). Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis. Cancer Lett, 239, 157-67.
  5. Singh KP, Kumari R, Treas J, DuMond JW (2011). Chronic exposure to arsenic causes increased cell survival, DNA damage, and increased expression of mitochondrial transcription factor A (mtTFA) in human prostate epithelial cells. Chem Res Toxicol, 24, 340-9.
  6. Smith TR, Miller MS, Lohman K, et al (2003). Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett, 190, 183-90.
  7. Sobti RC, Berhane N, Melese S, et al (2012). Impact of XPD gene polymorphism on risk of prostate cancer on north Indian population. Mol Cell Biochem, 362, 263-8.
  8. Tang D, Liu JJ, Rundle A, et al (2007) Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomark Prev, 16, 803-8.
  9. Wheless L, Kistner-Griffin E, Jorgensen TJ, et al (2012). A community-based study of nucleotide excision repair polymorphisms in relation to the risk of non-melanoma skin cancer. J Invest Dermatol, 132, 1354-62.
  10. Wu Q, Christensen LA, Legerski RJ, Vasquez KM (2005). Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep, 6, 551-7.
  11. Agalliu I, Kwon EM, Salinas CA, et al (2010). Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control, 21, 289-300.
  12. Berhane N, Sobti RC, Mahdi SA (2012). DNA repair genes polymorphism (XPG and XRCC1) and association of prostate cancer in a north Indian population. Mol Biol Rep, 39, 2471-9.
  13. Farrell J, Petrovics G, McLeod DG, Srivastava S (2013). Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men. Int J Mol Sci, 14, 15510-31.
  14. Chang CH, Chiu CF, Wang HC, et al (2009). Significant association of ERCC6 single nucleotide polymorphisms with bladder cancer susceptibility in Taiwan. Anticancer Res, 29, 5121-4.
  15. Chen J, Cui X, Zhou H, et al (2013). Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer, 13, 356.
  16. Dizdaroglu M (2012). Oxidatively induced DNA damage: mechanisms, repair and disease. Cancer Lett, 327, 26-47.
  17. Grant WB (2004). A multi country ecologic study of risk and risk reduction factors for prostate cancer mortality. Eur Urol, 45, 271-9.
  18. Globocan 2008 (2008). Prostate Cancer Incidence, Mortality and Prevalence Worldwide in 2008. International Agency for Research on Cancer.
  19. Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 1513-30.
  20. Grunda JM, Fiveash J, Palmer CA, et al (2010). Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clin Cancer Res, 16, 2890-8.
  21. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA (2008). NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis, 11, 349-56.
  22. Liao SG, Liu L, Wang Y, et al (2012). XPD Asp312Asn polymorphism is a risk factor for prostate cancer. J Cancer Res Clin Oncol, 138, 1689-95.
  23. Hu JJ, Mohrenweiser HW, Bell DA, Leadon SA, Miller MS (2002). Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol, 185, 64-73.
  24. Hu JJ, Hall MC, Grossman L, et al (2004). Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res, 64, 1197-201.
  25. Hyytinen ER, Frierson HF Jr, Sipe TW, et al (1999). Loss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer. Prostate, 41, 190-5.<190::AID-PROS6>3.0.CO;2-2
  26. Mittal RD, Mandal RK (2012). Genetic variation in nucleotide excision repair pathway genes influence prostate and bladder cancer susceptibility in North Indian population. Indian J Hum Genet, 18, 47-55.
  27. Neumann AS, Sturgis EM, Wei Q (2005). Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog, 42, 65-92.

Cited by

  1. Associations of ERCC4 rs1800067 Polymorphism with Cancer Risk: an Updated Meta-analysis vol.15, pp.18, 2014,
  2. Allele and Genotype Distributions of DNA Repair Gene Polymorphisms in South Indian Healthy Population vol.6, pp.1179-299X, 2014,
  3. Homozygous Wildtype of XPD K751Q Polymorphism Is Associated with Increased Risk of Nasopharyngeal Carcinoma in Malaysian Population vol.10, pp.6, 2015,
  4. Evaluation of Environmental Risk Factors for Prostate Cancer in a Population of Iranian Patients vol.15, pp.24, 2015,
  5. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men vol.16, pp.14, 2015,
  6. Significant Association of Alpha-Methylacyl-CoA Racemase Gene Polymorphisms with Susceptibility to Prostate Cancer: a Meta-Analysis vol.16, pp.5, 2015,
  7. gene with neuroblastoma risk in a Chinese population vol.20, pp.8, 2016,
  8. The association between XPG polymorphisms and cancer susceptibility vol.96, pp.32, 2017,